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Abstract
Background: Alterations in the dopamine transmission and receptor density are hypothesized in
the pathophysiology of schizophrenia but ethnic disparities are reported to exist in disease
association and therapeutic response to psychotropic medication. Antipsychotics have higher
binding affinity to D2 subtype of dopamine receptor. DRD2 Cys311, TaqIB1 and TaqIA1 variants
are considered to have either reduced affinity for dopamine and hypo-dopaminergic activity.
Methods: We examined the role of Taq1B, Taq1D, S311C, H313H and Taq1A polymorphisms of
DRD2 gene in schizophrenia and antipsychotic treatment response in 213 patients and 196
controls from a homogenous South Indian population. A more detailed genotype phenotype
association analysis was carried out to understand the disease in terms of its socio-cultural factors.
Results: H313HTT genotype was found to be associated with schizophrenia (P = 0.004) while
TaqIB1B1 genotype was significantly associated with higher psychopathology score. When
treatment response was considered H313HCC, TaqIA2A2 and Taq1D1D1 had higher mean
improvement scores. TaqID1D1 and H313HTT genotype were found to be significantly higher in
responders than in nonresponder group. Distinct shift in the LD patterns of responder and non-
responder group was observed. Certain symptoms were characteristic of our patient population.
Following medication the scores and presentation of these symptoms tend to vary in the responder
and non-responder groups.
Conclusion: Based on genotype phenotype correlations it can be suggested that certain
polymorphisms can be defined for their critical functions in disease and their role in treatment
response in South Indian population. The present study suggests that in addition to ethnic bias,
socio-cultural factors should also be considered while evaluating genotype phenotype correlations,
in association and treatment response to complex disorders like schizophrenia.
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Schizophrenia is a common but complex disorder, with
no consensus on the prevalence rate of this disease in
India. There appears to be no clear pockets of high or low
prevalence of schizophrenia in Indian population [1]. On
the other hand, the incidences of the factors that associate
with schizophrenia such as, economic status, migration
[2] and suicidal tendencies are three to four fold higher in
the state of Kerala, South India, than the national average.
Family, twin and adoption studies suggest that genetic fac-
tors play a significant role in the etiology of schizophrenia
[3]. Alterations in the dopamine transmission and recep-
tor density have been hypothesized in the pathophysiol-
ogy of schizophrenia [4]. Pharmacological observations
reveal that excess dopaminergic activity lead to the psy-
chotic symptoms of this disorder [5-7]. Several studies
have shown positive association of D2 subtype of
dopamine receptor (DRD2) in schizophrenia [8-12] how-
ever, this was refuted by many others [13-16]. Therefore,
it has been suggested that population gene frequencies
have to be considered when interpreting the association
between an allele and a disease because there is a chance
that association might be due to a stratified ethnic back-
ground rather than a direct causal relation. Similarly, eth-
nic disparities have also been observed in response to
psychotropic medication. Antipsychotics have higher
binding affinity to D2 subtype of dopamine receptor
(DRD2) in schizophrenic patients [17]. This binding
affinity is strongly correlated with the efficacy of the drugs
in controlling the positive symptoms of schizophrenia
[18]. Therefore mutations in DRD2 receptor might have
variable effect on the presentation of symptom and treat-
ment response. DRD2 has 8 exons and several of the SNPs
in the DRD2 gene have been screened for association with
the disease. Among the three non-silent mutations DRD2
V96A, P310S, S311C in the exonic region of DRD2,
S311C has been reported to have significant association in
several world populations [19]. Earlier studies have
shown that Cys311 variant of DRD2 has half the affinity
for dopamine in comparison to its wild type variant [20].
DRD2 Taq1A and Taq1B polymorphisms support hypo-
dopaminergic activity. In vitro and in vivo studies suggest
that Taq1A1 and Taq1B1 alleles have reduced D2 density
in the striatum [21,22]. In contrast to association studies
very few studies have evaluated the role of DRD2 receptor
variants in treatment response. Most often the association
or treatment response studies have been conducted in
relation to schizophrenia and not in identifying the socio-
cultural factors that associate with schizophrenia in pre-
senting various symptoms.
The aim of the present study was to investigate the
involvement of various alleles, genotypes, haplotypes and
their linkage disequilibrium status of Taq1B (rs 1079597),
Taq1D (rs1800498), S311C (rs1801028), H313H (rs
6275), and Taq1A (rs 1800497) polymorphisms in DRD2
receptor gene in causing schizophrenia and their relation
to treatment response in a South Indian population of
Kerala. The study was further aimed at understanding the
socio-cultural factors that associate with schizophrenia in




Subjects included 213 schizophrenic patients (81 Males
and 132 Females) with mean age 34.40 ± 10.86 of South
Indian state, Kerala. All the patients were diagnosed as per
the DSM-IV criteria [23] for mental disorders. Complete
patient history, their medication and follow up of all the
patients were maintained for independent review. Two
independent psychiatrists and a clinical pharmacologist
further assessed the patient history, diagnosis and medica-
tion of these patients. Baseline rating of the patients based
on Extended Brief Psychiatric Rating Scale (BPRS-E, 24
item, score 1–7) [24] was done at the time of first consul-
tation. Medication profile was monitored for all the fol-
low up periods. The study was set in its natural
background, therefore, the patients were not controlled
for their medication with antipsychotics. Majority of the
patients had been given both typical and atypical antipsy-
chotics as per their medical requirements. The most fre-
quently administered drugs were clozapine, haloperidol
and risperidone. The chlorpromazine equivalents ranged
from 423.8 ± 253.9 mg per day. One-year follow up was
considered for evaluating the treatment response. Clinical
improvement was assessed by percent change scores
between initial baseline BPRS score and BPRS score after
one-year follow-up [25]. Out of the 213 patients, 181
patients completed the one year follow-up. Patients were
classified into responders and non-responders by stand-
ard one scale criteria for evaluating response to antipsy-
chotics. In standard one-scale criteria the patients with
improvement of 50% or more in their BPRS ratings after
one year follow up were classified as "responders" and
others as "non responders". 122 patients met the criteria
of "responders" and 59 as "nonresponders" to antipsy-
chotic treatments. Control samples included 196 ethni-
cally and age matched random individuals who had no
family history of schizophrenia and had never taken any
neuroleptics in their lifetime. For understanding the
socio-cultural factors each individual symptom was
assessed for their overall representation (frequency) in the
disease population while the psychopathology (severity)
of symptoms was assessed by the BPRS score of each indi-
vidual symptom. Frequency was represented by presence
or absence of each individual symptom presented in the
patient population without considering the BPRS scores
while severity was represented based on the BPRS ratingPage 2 of 12
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tion. Similar evaluation of frequency and severity of
symptom was done in the responder and non responder
patient groups too.
Genotyping
Peripheral blood was collected from all the individuals in
EDTA coated vials. The study was approved by Institu-
tional Ethics Committee for biomedical subjects as per the
ICMR guidelines. Genomic DNA was isolated from lym-
phocytes according to Sambrook and Russell [26]. DRD2
SNPs were screened as described earlier for S311C [27],
H313H [28], TaqIA [29], TaqIB and TaqID [30]. PCR was
carried out in a total volume of 25 µl containing 100 ng
DNA, 200 µM dNTP, 1 µM of each primer, 1X buffer
(NEB, Inc., USA) and 0.5 units of Taq polymerase (NEB,
Inc., USA). PCR was programmed for initial denaturation
at 94°C for 3 min followed by 35 cycles of denaturation
at 94°C for 30 s, annealing for 45 s (depending on the
primer), extension at 72°C for 1 min and a final extension
of 72°C for 5 min in a Eppendorf Mastercycler (Table 1).
PCR products were digested with restriction enzymes
(depending on the nature of polymorphism) according to
manufacturer's protocol (NEB, Inc., USA), separated on
3% agarose gel and stained with ethidium bromide for
visualisation.
Statistical analysis
Allele frequency, genotype frequency, Hardy-Weinberg's
equilibrium, linkage disequilibrium (LD) and haplotype
frequencies were calculated with the software
COCAPHASE [31]. LD was analyzed and plotted using
Haploview [32]. Statistical comparison of clinical variable
and categorical data between the patients and controls
were analyzed using Chi-square (χ2) test. Fisher's exact t-
test was used whenever necessary. A "P" value of <0.05
was considered to be statistically significant. Odds ratio
(OR) and confidence interval was also calculated wher-
ever required. To reveal the basic structure of the findings,
the baseline characteristics were analyzed. Mann Whitney
U test was used to understand the relation between geno-
types and severity of each individual symptom at initial
presentation and after one year follow-up. This was done
by the SPSS version 11 software program.
Results
Demographic features of the subjects are given in Table 2.
No significant difference was observed in the age of onset
between the genders. No preference of gender and disease
was observed. Baseline BPRS scores and percent improve-
ment score also did not vary between the genders. The
allele and genotype frequencies of DRD2 SNPs are shown
in Table 3. None of the SNPs show deviation from Hardy-
Weinberg's equilibrium in the patient and control popu-
lation.
DRD2 association with schizophrenia
When the allele frequencies were compared between cases
and controls we did not find any significant association
with any of the individual SNPs with the disease. Interest-
ingly the homozygous genotype of alleles that represented
lower dopaminergic activity or reduced receptor density,
were less frequent in our study population. However,
when the role of individual genotype frequencies were
compared for disease association, DRD2 H313H TT geno-
type was found to be significantly associated with the dis-
ease (P = 0.008, χ2 = 9.60, df = 2). While using a model
based approach for disease association a similar signifi-
cant positive association of H313H with TT genotype in
dominant model (TT Vs TC+CC, P = 0.0045), was
observed while DRD2 TaqIA with A1A1 genotype in a
recessive model (A1A1 Vs A1A2+A2A2, P = 0.029) was
observed as a protective genotype for the disease (Table
3). On further analysis with 2 to 5 marker haplotypes, we
observed a distinct pattern of haplotypes in cases and con-
trols and several haplotypes were found to be significantly
associated (Table 4). Haplotype frequency less than 5% in
both the groups were not considered for interpretation.
DRD2 H313H with T allele and Taq1A with A2 allele were
observed to be common in 2 and 3 locus haplotypic asso-
ciation with the disease. The C allele of H313H seems to
be associated with protective haplotype in majority of the
Table 1: PCR primers, annealing temperatures for PCR and the restriction enzymes used to detect different DRD2 polymorphisms.
Polymorphism Primers Annealing temp. Restriction Enzyme
Taq1B F 5'GATACCCACTTCAGGAAGTC 3'
R 5'GATGTGTAGGAATTAGCCAGG 3'
60°C Taq1A
Taq1D F 5'CCCAGCAGGGAGAGGGAGTA 3'
R 5'GACAAGTACTTGGTAAGCATG 3'
60°C Taq1A
S311C F 5'TTGGGCATGGTCTGGATCTCAAA 3'
R 5'CCAGCTGACTCTCCCCGACCGGT 3'
65°C Sau961
H313H F 5'ATCCTGCAGCCATGG 3'
R 5'ATTGTCCGGCTTTACC 3'
55°C Nco1
Taq1A F 5'CCCTTCCTGAGTGTCATCA 3'
R 5'CGGCTGGCCAAGTTGTCTA 3'
58°C Taq1APage 3 of 12
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observed between TaqI "B" and TaqI "D" and between
TaqI "B" and TaqI "A in the control group, however, in the
same pairwise combinations in the patient group, a shift
in the pattern of LD was observed (Fig 1). In the patient
group the pairwise LD between the TaqI "B" and TaqI "A"
reduced while between TaqI "D" and "S311C"a very dis-
tinctive increase was observed.
None of the alleles or genotypes was found to be associ-
ated with early onset schizophrenia, though a non signif-
icant trend was observed for TaqI B2B2 genotype with age
of onset below 20 (Data not shown). Patients were further
assessed for their extent of psychopathological symptoms
based on their BPRS rating at initial presentation. Using
Mann Whitney U test for all genotype and overall disease
phenotype correlations, we observed that among all gen-
otype comparisons, TaqI B1B1 genotype individuals
showed significantly higher (P = 0.017) psychopathology
scores (Data not shown).
DRD2 association with treatment response in 
schizophrenia
Out of 213 patients the BPRS rating with one year follow
up was available for only 181 individuals. Out of 181
patients 100% improvement in BPRS score was observed
in only 9 patients. When the common genotypes were
compared in these nine patients, we observed that TaqI
A2A2 and TaqI B2B2 genotypes were present in 88.87 %
of these patients. Average percentage improvement after
one year follow up was observed to be 60%. When indi-
vidual genotypes were compared using Mann-Whitney U
test for overall improvement, we observed that H313H
CC genotype, TaqI A2A2 and TaqI D1D1 genotype had a
significantly higher mean percent improvement when
compared to TC genotypes (P = 0.042), A1A2 genotype (P
= 0.0487), D1D2 (P = 0.0066) and also D2D2 genotype
(P = 0.01) respectively (see Additional file).
The patients were further classified into responder and
non responder groups based on 50% improvement crite-
ria. Based on this threshold, 67% of the individuals were
observed to fall in the responder group. None of the indi-
vidual SNPs showed any association with the responder
and the non-responder patient group (Table 5). However,
while considering a model based approach we observed
that DRD2 Taq1D with D1D1 genotype in a recessive
model (D1D1 vs D1D2 + D2D2, P = 0.0226) and H313H
with TT genotype in a dominant model (TT vs TC + CC, P
= 0.049) show significant association with the responder
group (Table 5). Interestingly the H313H TT genotype
that was significantly associated with the disease was also
found to be associated with good response to medication.
Patients with poor dopaminergic genotypes 311Cys Cys
and TaqI A1A1 were not found to have any relationship
with treatment response. The responder and non-
Table 3: Allele and genotype frequencies of dopamine receptor polymorphisms in patient and control groups.
Locus Genotype Frequency χ2 P Allele Frequency χ2 P
Taq1B (rs 1079597) B1B1 B1B2 B2B2 2.0 0.36 B1 B2 0.03 0.86
Cases (n = 212) 0.05(11) 0.41(86) 0.54(115) 0.25(108) 0.75(316)
Controls (n = 196) 0.08(16) 0.36(70) 0.56(110) 0.26(102) 0.74(290)
Taq1D (rs 1800498) D1D1 D1D2 D2D2 2.49 0.29 D1 D2 0.004 0.95
Cases (n = 211) 0.12(25) 0.58(123) 0.30(63) 0.41(173) 0.59(249)
Controls (n = 195) 0.15(30) 0.51(99) 0.34(66) 0.41(159) 0.59(231)
S311C (rs 1801028) GG GC CC 0.41 0.81 G C 0.01 0.92
Cases (n = 210) 0.80(169) 0.18(38) 0.10(3) 0.89(376) 0.11(44)
Controls (n = 195) 0.81(159) 0.16(32) 0.02(4) 0.90(350) 0.10(40)
H313H1 (rs 6275) TT TC CC 9.60 0.008* T C 2.92 0.09
Cases (n = 213) 0.36(76) 0.43(92) 0.21(45) 0.57(244) 0.43(182)
Controls (n = 193) 0.23(44) 0.57(110) 0.20(39) 0.51(198) 0.49(188)
Taq1A2 (rs 1800497) A1A1 A1A2 A2A2 4.88 0.09 A1 A2 0.57 0.45
Cases (n = 212) 0.08(17) 0.44(93) 0.48(102) 0.30(127) 0.70(297)
Controls (n = 194) 0.15(29) 0.40(77) 0.45(88) 0.35(135) 0.65(253)
1H313H dominant model (TT Vs TC+CC) P = 0.0045, Odds = 1.879, CI = 1.212 to 2.911
2 Taq1A recessive model (A1A1 Vs A1A2+A2A2) P = 0.029, Odds = 0.4960, CI = 0.2632 to 0.9348
Table 2: Demographic characteristics of patient population.
Sex (n) Mean Age Mean Age of onset BPRS Baseline Score Final BPRS Sore Mean % change in BPRS Score
F (132) 33.95 ± 12.9 24.10 ± 8.73 62.23 ± 11.59 39.30 ± 10.10 61.87 ± 23.38
M (81) 33.36 ± 8.9 24.95 ± 6.77 59.11 ± 9.58 37.91 ± 9.108 58.50 ± 30.62Page 4 of 12
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haplotypic associations with similar 5% threshold as cut
off for interpretation. We found that TaqI B2 and TaqI D1
were significantly high in responders group and were pre-
sented frequently in several haplotypic combinations.
While TaqI D2 and G allele in S311C polymorphism has
been observed to be significantly higher and frequently
represented in different haplotypic combinations in the
non-responder group (Table 6). Pairwise LD between the
SNPs in the responder and non responder patients varied.
The LD between TaqI "B" and "D", and TaqI "B" and "A"
in the responder group was similar to the overall patient
group, while in the non responder group the pairwise LD
drastically reduced in all combinations (Fig 2).
Evaluation of symptoms
We further tried to understand the disease in terms of its
symptoms, which is believed to be influenced by socio-
cultural factors that are associated with South Indian pop-
ulation. Symptoms were assessed for their frequency of
presentation and psychopathological scores as described
earlier. Representation of individual symptoms above
40% and psychopathology subscores above 3 were only
considered for interpretation. Representation of various
symptoms in the patient population is shown in Fig 3.
Certain positive symptoms such as suspiciousness, hallu-
cinations, bizarre behaviour and hostility and certain neg-
ative symptoms such as self neglect, blunted effect,
emotional withdrawal and uncooperativeness are the
major characteristic symptoms that represented our
patient population. Cognitive symptoms such as unusual
thought content are also highly represented in our patient
population. All these symptoms were represented in more
than 60 percent of the patient population. Same set of
symptoms were also found to be chronic in presentation
when the severity of the symptoms were assessed, how-
ever, the severity of the presentation varied (Fig 4).
In a one year follow up assessment, majority of the symp-
toms were observed to have improved, in the patient pop-
ulation. However, when the same assessment was done in
the responder and non-responder patient group, we
observed that the representation of symptoms varied in
responder and non responder groups. In responder group
the representation of certain symptoms such as bizarre
behaviour, self neglect, hostility and unusual thought
content reduced drastically while a reverse trend was
observed in the non-responder group (Fig 3). The symp-
toms such as bizarre behaviour, self neglect, emotional
withdrawal and blunted effect had increased representa-
tion while hallucinations, suspiciousness and uncoopera-
tiveness display minimal change from initial score in the
non responder group. Aggressive symptoms such as hos-
tility seem to have significantly reduced in its representa-
tion in both the groups.
Severity of symptoms was also observed to decrease in all
the patients. However, when responder and non-
responder groups were compared, the severity scores in
the responder group were observed to decrease drastically
when compared to non-responder group (Fig 4). In the
responder group the severity scores decreased by a score of
1.5–2 while in the non responder group it decreased by 1–
1.5 in a 0–6 point scale. Based on these thresholds of
scores in the responder and non responder groups we
found that emotional withdrawal and blunted effect had
no improvement in the non-responder group while in
responder group symptoms such as blunted effect, self
neglect and bizarre behaviour had marginal improvement
in their severity scores.
Evaluation of symptoms and genotype
After understanding the disease in terms of its symptoms,
it was important to understand the relationship of geno-
type to a specific phenotype (symptom). Mann Whitney U
test was used to compare the genotypes and their relation-
ship with each individual's initial BPRS scores for each
symptom (Table 7). The test was independent of overall
presentation of symptom in a particular genotype. Among
the positive symptoms, severe hallucination was observed
to be significantly associated with Taq1 B1B1 genotype.
While among the negative symptoms, severe self neglect
LD patterns of DRD2 SNPs in cases (a) and controls (b)Figure 1
LD patterns of DRD2 SNPs in cases (a) and controls (b).
Table 4: Two – Five marker haplotype frequency in patient and 
control groups.
Haplotype frequency
Locus Haplotype Cases Controls P Odds
Locus 4-5 1-2 38.12 30.34 0.024 1.41
Locus 3-4-5 1-1-2 35.5 28 0.029 1.44
Locus 
1-2-3-4
1-1-1-2 4.6 0.2 0.019 33.94
Locus 
1-2-3-4
2-1-1-2 4.9 11.5 0.012 6.34
Locus 
1-2-3-4-5
2-1-1-2-2 3.95 10.72 0.009 6.72Page 5 of 12
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H313H TC and TT genotype. DRD2 Taq1 A1A1 and A1A2
genotypes were found to be significantly associated with
severe self neglect symptoms in schizophrenic patients.
Subsequently, we also tried to understand the genotype
phenotype relationship in response to medication. It was
observed that in response to medication, the Taq1 D1D1
genotype individuals display improved response in posi-
tive symptoms like suspiciousness, hallucination and
bizarre behavior (Table 8). Individuals heterozygous for
DRD2 H313H TC genotype show poor response to medi-
cation for hallucination. However, among negative symp-
toms, uncooperative behavior was observed to be
associated with reduced impact of medication in
homozygous DRD2 H313H TT genotype individuals.
DRD2 Taq1 A2A2 and B2B2 genotype was observed to be
associated with improvement of self neglect symptom.
Discussion
Alterations in dopamine transmission and dopamine
receptors particularly the D2 receptor have long been
hypothesized in the pathophysiology of schizophrenia
[8,17]. In the past, several studies have been carried out to
identify the role of DRD2 polymorphism representing
variable receptor densities in schizophrenia [8]. Very few
studies have been carried out to evaluate the treatment
response of antipsychotics in schizophrenia [33,34].
Racial disparities have been observed in associating vari-
ous DRD2 SNPs in causing the disease and also in evalu-
ating the treatment response. In the present study the role
of various DRD2 SNPs in causing the disease and treat-
ment response of antipsychotics in a more homogeneous
population of South India were examined. In addition, we
also assess the genotype phenotype correlations based on
presentation of individual symptoms and their severity in
disease manifestation and treatment response. This is
probably the first study which tries to dissect the role of
DRD2 polymorphisms in schizophrenia to the level of
symptoms. Therefore, an exploratory study of this kind
will enhance the understanding of critical factors such as
ethnicity, social and cultural events involved in assessing
the disease and treatment response.
Table 6: Two – Five marker haplotype frequency in the responder and non responder groups in patient population based on percent 
response score ≤ 50% ≥.
Haplotype frequency
Locus Haplotype Responders Nonresponders P Odds
Locus 4-5 2-1 8.7 18.75 0.0084 2.46
Locus 3-4-5 1-2-1 7.17 16.7 0.0274 4.86
Locus 2-3-4-5 1-1-2-1 2.93 9.73 0.049 3.87
Table 5: Allele and genotype frequencies of dopamine receptor polymorphism in responder and non responder groups in patient 
population based on percent response score ≤ 50% ≥.
Locus Genotype Frequency χ2 P Allele Frequency χ2 P
Taq1B (rs 1079597) B1B1 B1B2 B2B2 0.18 0.915 B1 B2 0.15 0.7
Responders(n = 121) 0.04(5) 0.42(51) 0.54(65) 0.25(61) 0.751(181)
Nonresponders(n = 59) 0.05(3) 0.44(26) 0.51(30) 0.27(32) 0.73(86)
Taq1D 1 (rs 1800498) D1D1 D1D2 D2D2 6.14 0.046* D1 D2 0.65 0.42
Responders (n = 121) 0.15(18) 0.54(65) 0.31(38) 0.42(101) 0.58(141)
Nonresponders(n = 59) 0.03(2) 0.68(40) 0.29(17) 0.37(44) 0.63(74)
S311C (rs 1801028) GG GC CC 0.99 0.61 G C 0.26 0.61
Responders (n = 120) 0.79(95) 0.19(23) 0.02(2) 0.89(213) 0.11(27)
Nonresponders(n = 58) 0.81(47) 0.19(11) (0) 0.90 (105) 0.10(11)
H313H2 (rs 6275) TT TC CC 5.57 0.06 T C 1.76 0.18
Responders (n = 122) 0.36(44) 0.41(50) 0.23(28) 0.57(138) 0.43(106)
Nonresponders(n = 59) 0.20(12) 0.58(34) 0.22(13) 0.49(58) 0.51(60)
Taq1A (rs 1800497) A1A1 A1A2 A2A2 1.91 0.39 A1 A2 1.44 0.23
Responders (n = 121) 0.09(10) 0.42(51) 0.49(60) 0.29(71) 0.71(171)
Nonresponders(n = 59) 0.08(5) 0.53(31) 0.39(23) 0.35(41) 0.65(74)
1Taq1D recessive model (D1D1vs D1D2 +D2D2) P = 0.023, Odds = 4.98, CI = 1.115 to 22.25
2H313H dominant model (TT Vs TC+CC) P = 0.0490, Odds = 0.490, CI = 0.2394 to 1.004Page 6 of 12
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In the present study we could find a strong association of
DRD2 H313H TT genotype with the disease. This poly-
morphism has not been in focus in association studies of
schizophrenia before. In a recent study, this synonymous
polymorphism was reported to be associated with schizo-
phrenia in a South Indian population using a sample size
of 101 individuals [12]. Interestingly, this study reported
significantly higher association with H313H TT genotype
in a recessive model which is in contrast to our observa-
tion on association of TT genotype using a dominant
model as we observed higher H313H T allele frequency in
our study population. This discrepancy could be due to
sample size and population structure of the sampled pop-
ulation in a genetically diverse South Indian states. We
further observed that the DRD2 Cys311 allele frequency
(0.11 in patients and 0.10 in controls) was high in our
South Indian population when compared with different
world populations. The Cys311 allele frequency has been
reported to range from 0.01 to 0.05 in Europeans and
0.00 to 0.06 in Asian population while our Cys311 allele
frequency was comparable to North American Pima
Indian population [19,35]. Arinami et al. [9] reported a
positive association of the Cys311 allele with schizophre-
nia. But most of the later studies failed to support the
argument that Cys311 allele of DRD2 poses a genetic risk
factor for schizophrenia [14,20,36-42]. Meta-analyses of
case control studies with DRD2 S311C provides strong
evidence that Cys311 allele of DRD2 influences suscepti-
bility to schizophrenia and that the risk associated with
this polymorphism is actually greater than either HTR2A
or DRD3 [19]. However, in the present study higher
Cys311 allele frequency, does not support the association
of Cys311 allele or genotype with schizophrenia but sug-
gest for an ethnic bias in South Indian population. Golim-
bet et al. [43] suggested that TaqI A2A2 genotype may be
a potential genetic factor for susceptibility to schizophre-
nia. Higher frequency of TaqI A2A2 genotype in our
patient and control population was observed but no pos-
itive association with the disease could be established.
However, in haplotypic combinations Taq1 A2 and
H313H T alleles were significantly associated with the dis-
ease. This suggests that predisposition of an allele for any
disease needs to be understood in terms of its haplotypic
associations.
Therapeutic response of DRD2 variants
Ethnic disparities in the prescription of antipsychotic
drugs and their response in schizophrenic patients have
been reported extensively [44-46]. Effective known treat-
ments for schizophrenia are those that principally antago-
Frequency of symptoms represented at initial presentation compared with presentation of symptoms after one year follow up of medicati n in responder and on responder patientsigur  3
Frequency of symptoms represented at initial presentation compared with presentation of symptoms after one year follow up 
of medication in responder and non responder patients.
LD patterns of DRD2 SNPs in responders (a) and non responders (b)Figure 2
LD patterns of DRD2 SNPs in responders (a) and non 
responders (b).Page 7 of 12
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known antipsychotic drugs have potent affinities for the
DRD2 receptor. Functional brain imaging studies have
suggested DRD2 receptor binding by antipsychotic agents
may be necessary and sufficient for antipsychotic efficacy
[13]. Therefore, the DRD2 receptor gene becomes an obvi-
ous candidate for pharmacogenetic studies of antipsy-
chotic drug response in schizophrenia. But not much of
information is available on therapeutic response of antip-
sychotics in relation to DRD2 variants in schizophrenia.
Differences in allelic or genotypic associations were
observed with treatment response, in diverse ethnic
groups. Recently DRD2 Taq1A1 allele has been correlated
with favorable antipsychotic response [48]. Functionally
A1 allele has been suggested to diminish dopaminergic
activity in the CNS viz. prolonged p300 latency, reduced
visuo-spatial function and reduced brain glucose metabo-
lism [49]. Earlier reports also suggested that DRD2
Taq1A2A2 genotype individuals display poorer clinical
response than their heterozygous counterparts [50] and
this distinction was achieved within two weeks of treat-
ment [51]. Our study did not find any difference in allele
and genotype frequencies of Taq1A in responder and non
responder groups. Hwang et al. [33] has reported that in
Taq1B polymorphism, Taq1 B2 allele is associated with
response to clozapine in African-American sample but not
Severity of symptoms based on initial BPRS score compared with the BPRS score after one year follow up of medication in r sponder and non respon er patientsFigu e 4
Severity of symptoms based on initial BPRS score compared with the BPRS score after one year follow up of medication in 
responder and non responder patients.
Table 7: Relationship of genotype to a specific symptom in patient population based on BPRS score at initial presentation.
Symptom Polymorphism n Genotype n P value
Hallucination Taq1B 68 B1B1 Vs B1B2 B1B1 5 0.0032
B1B2 63
83 B1B1 Vs B2B2 B1B1 5 0.0031
B2B2 78
Self neglect His313His 107 CC Vs TC CC 39 0.019
TC 68
Taq1A 79 A1A1 Vs A2A2 A1A1 12 0.045
A2A2 67




His313His 107 CC Vs TC CC 39 0.04
TC 68
79 CC Vs TT CC 39 0.001
TT 40Page 8 of 12
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our sample, when allele and genotype associations were
compared. Hwang et al. [33] has studied Taq1D polymor-
phism in Caucasian as well as African – American popula-
tion, but did not find any significant observation for
response to clozapine. In contrast, our study found signif-
icant association of D1D1 genotype in responders when
compared to nonresponder group (p = 0.023) in a reces-
sive model. Recently another DRD2 S311C variant has
also been shown to have general treatment response to
several atypical antipsychotics [52] which could not be
confirmed in our study. Interestingly, the H313H TT gen-
otype which was strongly associated with the disease was
also found to be associated with good response (p =
0.0490). At this point it is difficult to interpret the func-
tional significance for this tendency but it can be hypoth-
esized that its linkage with other polymorphisms might
be vital in altering the therapeutic response. In the present
study we found that, the Taq1B, Taq1D, S311C and
H313H were mainly associated with response, where B2
and D1 were associated with good response while Cys 311
and H313H C were associated with poor response. Hwang
et al. [33] reported that among DRD2 SNPs, Taq1A,
Taq1B and rs 1125394 could be used as markers for cloz-
apine response in African-American patients while this
does not hold true for Caucasian. Discrepancies between
different studies are largely due to methods of evaluating
response. It is difficult to generalize the response of single
drug with multiple drugs, variable time intervals for eval-
uating response and classifying responders and non
responders with different threshold for response. Besides
the response scores are overall generalized scores. There-
fore, in order to address this discrepancy, it would be ideal
to understand the disease in terms of its presentation of
symptoms in a particular ethnic group.
Response of symptoms in general and in association to 
DRD2 variants
Dopamine receptors are involved in various responses
such as motor control, neuroendocrine regulation, cogni-
tion, emotion and drug abuse that are critically impaired
or associated with schizophrenia. In schizophrenia, it is
not only ethnicity but various socio-cultural factors can
also influence a particular symptom. In the present study,
these socio-cultural factors are addressed by understand-
ing the presentation of symptoms in the study population
and subsequently evaluating the symptom and treatment
response in relation to its genotype. We observed that
60% of the patient population presented certain positive
symptoms such as suspiciousness, hallucinations, hostil-
ity and bizarre behavior and certain negative symptoms
such as self neglect, blunted effect, emotional withdrawal
and uncooperativeness. Cognitive symptom such as unu-
sual thought content was also observed to be highly rep-
resented in the patient population. Same set of symptoms
were also found to be chronic in presentation when sever-
ity of the symptoms were assessed, however, the severity
of the presentation varied. Assessment of symptoms based
on one year follow up of antipsychotic medication indi-
cated that the presentation of symptoms varied in
responder and non responder groups. In responder group
the representation of bizarre behaviour, self neglect, hos-
tility and unusual thought content reduced drastically
while a reverse trend was observed in the non-responder
Table 8: Relationship of genotype to a specific symptom in patient population based on BPRS score after one year follow-up.
Symptom Polymorphism n Genotype n P value
Suspiciousness Taq1D1 102 D1D1 Vs D1D2 D1D1 14 0.023
D1D2 88
55 D1D1 Vs D2D2 D1D1 14 0.04
D2D2 41
Hallucination His313His 105 CC Vs TC CC 38 0.06
TC 67
106 TC Vs TT TC 67 0.03
TT 39
Taq1D 55 D1D1 Vs D2D2 D1D1 14 0.03
D2D2 41
Bizarre Behavior Taq1D 55 D1D1 Vs D2D2 D1D1 14 0.045
D2D2 41
Self neglect Taq1A 76 A1A1 Vs A2A2 A1A1 11 0.03
A2A2 65
132 A1A2 Vs A2A2 A1A2 67 0.003
A2A2 65
Uncooperativeness His313His 105 CC Vs TC CC 38 0.02
TC 67
77 CC Vs TT CC 38 0.0015
TT 39Page 9 of 12
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reduced in its representation in both the group, while
blunted effect was observed to have been minimally
reduced or remained unchanged in its representation.
Even the severity scores of various symptoms in the
responder group were observed to decrease drastically
when compared to their non-responder group patients.
Similar variations in the presentation of symptoms have
been reported earlier. Patel et al. [53] reported that Cauca-
sian patients have more severe and persistent mood symp-
toms when compared to African-American and Hispanic
ethnic groups and also suggested that it may alter the
response to atypical antipsychotic risperidone in schizo-
affective disorders. Emsley et al. [54] has observed that
patients of Asian and Hispanic origin have better response
to antipsychotics at a low dose than Caucasian counter
parts. In a two-year follow up study involving eight coun-
tries, 50% of Indian schizophrenic patients were reported
to have recovered in India and 58% in Nigeria, but only
8% were reported as recovered in Denmark [55]. Thus it
can be suggested that ethnicity may play a role in presen-
tation of symptoms and treatment response but whether
there is any relation between dopaminergic activities
based on genotype to phenotype correlations is still not
clear. Therefore relating the phenotype to its correspond-
ing genotype seems to be crucial in understanding the het-
erogeneity of the disease.
A strong association of TaqI B1B1 genotype with severe
hallucination and TaqI A1A1 and A1A2 genotypes with
severe self neglect symptoms was observed. H313H TC
and TT genotypes were strongly associated with severe self
neglect and uncooperativeness respectively in schizo-
phrenic patients. Thus it can be suggested that in DRD2
TaqI A the A1 allele and in H313H the T allele are indica-
tive of severe psychopathological symptoms. While
assessing the relationship of genotype to a specific pheno-
type with response to medication, we observed better
response with TaqI D1D1 genotype for suspiciousness,
hallucination and bizarre behaviour while their alternate
homozygous genotypes are indicative of poor response to
medication for these symptoms. Heterozygous H313H TC
genotype individuals show poor response to medication
for hallucination symptom. However, among negative
symptoms homozygous H313H TT genotype was
observed to be associated with reduced impact of medica-
tion on uncooperative behaviour. DRD2 TaqI A2A2 and
B2B2 genotype was observed to be associated with
improvement of self neglect symptom. Interestingly, the
genotypes that were strongly associated with chronic pres-
entation of symptoms were not associated with good
response. However, H313H TT and TC genotypes that
were found to be associated with severe negative symp-
toms such as self neglect and uncooperativeness were also
found to be associated with poor response to medication.
Since the present study is exploratory in nature it is diffi-
cult to assign any specific functional role of these geno-
types to any specific symptom, as these symptoms are also
likely to be associated with multiple genes. In conclusion
it can be suggested that in South Indian population
H313H and TaqIA polymorphism are the most critical
polymorphism that are involved in predisposition to dis-
ease, presentation of individual symptoms and in treat-
ment response.
This presumably is the first exploratory study which
attempts to understand the genotype phenotype relation-
ship in a disease to the level of its individual symptoms.
The symptoms of schizophrenia are so complex in nature
that it needs adequate time and various drugs for appro-
priate response. Therefore, the study was set to its natural
background without controlling the antipsychotic medi-
cation till the one year follow-up period. Correction for
multiple hypotheses was not tested as this would drasti-
cally reduce the resolution of individual observation with
the available sample size. Therefore a larger study would
resolve the genotype phenotype correlations to the level
of individual symptoms more precisely. The present study
suggests that the disparity in the management of schizo-
phrenia should not only be interpreted from its ethnic
perspective but also through its relationship to social and
cultural events associated with genotype phenotype corre-
lations in a specific ethnic community.
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